Pharsight

Bracco patents expiration

1. Cardiotec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6056941 BRACCO Kit for the preparation of technetium TC 99m teboroxime myocardial perfusion agent
Jul, 2019

(4 years ago)

Drugs and Companies using TECHNETIUM TC-99M TEBOROXIME KIT ingredient

Market Authorisation Date: 19 December, 1990

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

CARDIOTEC family patents

Family Patents

2. Kinevac patents expiration

KINEVAC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6803046 BRACCO Sincalide formulations
Aug, 2022

(1 year, 9 months ago)

Drugs and Companies using SINCALIDE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

KINEVAC family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Lumason patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5686060 BRACCO Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography
Nov, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10232061 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(14 years from now)

US10335502 BRACCO Freeze-dried formulation for gas-filled microvesicles
Jul, 2038

(14 years from now)

US11723869 BRACCO Freeze-dried product and gas-filled microvesicles suspension
May, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-728) Mar 31, 2019
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Patient Population(NPP) Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

NCE-1 date: 10 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: Use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

LUMASON family patents

Family Patents

4. Prohance patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5474756 BRACCO Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2012

(11 years ago)

US6143274 BRACCO Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2012

(11 years ago)

US5846519 BRACCO Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2015

(8 years ago)

Drugs and Companies using GADOTERIDOL ingredient

Market Authorisation Date: 16 November, 1992

Treatment: Contrast agent for mri

Dosage: INJECTABLE;INJECTION

More Information on Dosage

PROHANCE family patents

Family Patents

5. Prohance Multipack patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5474756 BRACCO Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2012

(11 years ago)

US6143274 BRACCO Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2012

(11 years ago)

US5846519 BRACCO Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
Dec, 2015

(8 years ago)

Drugs and Companies using GADOTERIDOL ingredient

Market Authorisation Date: 09 October, 2003

Treatment: Contrast agent for magnetic resonance imaging

Dosage: INJECTABLE;INJECTION

More Information on Dosage

PROHANCE MULTIPACK family patents

Family Patents